Rituximab in Lymphocyte-Predominant Hodgkin Disease

Publisher： Karger

E-ISSN： 1423-0232|76|1|26-29

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.1, 2008-11, pp. : 26-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

By  

Acta Haematologica, Vol. 134, Iss. 3, 2015-05 ,pp. : 187-192

Karger

Access to resources Recommend Favorite

What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?

By  

Acta Haematologica, Vol. 134, Iss. 3, 2015-05 ,pp. : 185-186

Karger

Access to resources Recommend Favorite

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

By  

Case Reports in Oncology, Vol. 5, Iss. 2, 2012-08 ,pp. : 413-419

Karger

Access to resources Recommend Favorite

Identifying racial differences in nodular lymphocyte‐predominant Hodgkin lymphoma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3387-3389

John Wiley & Sons Inc

Access to resources Recommend Favorite

Race‐specific features and outcomes of nodular lymphocyte‐predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3472-3480

John Wiley & Sons Inc

Access to resources Recommend Favorite